Adcentrx to Present ADRX-0706 Clinical Data at ASCO 2025

Adcentrx Therapeutics, a clinical-stage biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs), is set to present groundbreaking clinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. This presentation marks a significant milestone for the company as it showcases the interim results from the Phase 1a dose escalation study of ADRX-0706, a next-generation Nectin-4 ADC.

ADRX-0706 represents a promising therapy designed to address the considerable unmet needs of patients with limited treatment options. The presentation by Adcentrx will be delivered through a poster session, offering insights into the differentiated safety and pharmacokinetic (PK) profiles of ADRX-0706. Notably, the data reveals a lower incidence of critical adverse events, such as peripheral neuropathy, which is a common concern in cancer treatments.

The preliminary efficacy signals observed across various dose levels and tumor types further substantiate the potential of Adcentrx's ADC platform. The company employs its proprietary i-Conjugation® technology and a novel auristatin payload, AP052, to enhance the efficacy and safety of ADRX-0706. This technology ensures a stable conjugation with a drug-antibody ratio of eight (DAR 8), which significantly expands the therapeutic window, as demonstrated in preclinical studies.

The Phase 1a/b study is an open-label, two-part trial, conducted at locations in the United States and China. The completed Phase 1a portion involved dose escalation to assess the initial safety and tolerability of ADRX-0706 in patients with advanced solid tumors. This phase aimed to establish the recommended dose for the subsequent Phase 1b portion of the trial.

The ongoing Phase 1b stage is designed to further evaluate the safety, tolerability, preliminary efficacy, and optimal dosing of ADRX-0706, specifically in patients with urothelial, triple-negative breast, and cervical cancers. The study's design underscores Adcentrx’s commitment to developing targeted therapies that provide meaningful benefits to cancer patients with limited treatment options.

The upcoming ASCO presentation will be titled "Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next-generation Nectin-4 ADC, in subjects with advanced solid tumors." It is scheduled for June 2, from 1:30 p.m. to 4:30 p.m. CST, under the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session. The full abstract will be published by ASCO in conjunction with the meeting.

Adcentrx's i-Conjugation® technology platform plays a critical role in the design of its ADCs, utilizing protease-cleavable linkers and stable conjugation chemistry to optimize payload delivery. This approach has allowed the company to create ADCs with enhanced stability and efficacy, addressing the challenges typically associated with ADC development.

ADRX-0706 itself is a fully proprietary ADC discovered by Adcentrx, targeting Nectin-4, a protein highly expressed in various solid tumors but with limited expression in normal tissues. This makes it a strategic target for ADC therapies, offering the potential for improved outcomes for patients with poor disease prognosis.

In conclusion, the presentation at the ASCO Annual Meeting signifies a pivotal moment for Adcentrx as it provides clinical proof of concept for its innovative technology platform. With ADRX-0706 demonstrating a favorable safety and efficacy profile, Adcentrx continues to advance its pipeline of ADCs with the aim of delivering transformative cancer therapies.